Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children

Figures & data

Figure 1. Distribution of enrolment age group with the baseline anti HAV antibody titer.

Table 1. Percentage seroconversion following single dose of live attenuated hepatitis A vaccine (at cut off value of >20mIU/ml) and GMC (excluding subjects antibody titer >10.000 mIU/mL)

			Excluding antibody titer >10,000 mIU/mL
Time	Subjects	Seropositivity rate (%) (at cut off value of >20mIU/ml)	GMC	95% CI
6 wk	334	95.1	64.9	58.4–72.2
6 mon	290	97.9	138.1	119.2–147.1
12 mon	186	98.3	135.2	110.4–147.7
24 mon	133	96.2	124.6	96.2–152.9
36 mon	135	97.8	137.6	104.5–149.2
48 mon	102	92.6	127.4	91.3–155.1
60 mon	111	97.3	127.1	70.1–156.3

Figure 2. Geometric mean concentration (GMC) for different age groups for subjects with baseline HAV antibody titer <20 mIU/mL including all tested subjects.

Figure 3. Reverse cumulative distribution curve of anti-HAV antibody titer at baseline and after 60 months post vaccination.